#metsera
#metsera

[ follow ]

Pfizer beats out Novo Nordisk in bidding for obesity drugmaker Metsera | Fortune

Pfizer will acquire development-stage obesity drugmaker Metsera for up to $86.25 per share, outbidding Novo Nordisk amid antitrust concerns.

Pfizer will acquire obesity startup Metsera for about $4.9bn, paying $47.50 per share plus up to $22.50 in milestone-based payments.

[ Load more ]